Instem of Conshohocken, Pa., a provider of IT solutions to the global early development healthcare market, has entered the early phase clinical trials market with its recent acquisition of Logos Technologies.
The latest release of the ALPHADAS software solution suite is a proactive eSource clinical trials system that is mobile, schedule-driven and provides real-time bedside or station-based direct data capture that virtually eliminates paper-based data. ALPHADAS delivers quality, operational efficiencies and time savings across the clinic, data management, recruitment, site administration and the laboratory.
The new system enhances Instem’s Study Workflow and Automation Suite that enables organizations of all sizes to collect, manage, review and submit study data that streamline processes, increase quality and enhance development programs.
Instem’s entry into the early clinical market provides greater access to early phase clinical data in both healthy and patient populations, advancing Instem’s translational informatics technology strategy. Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem has full offices in the U.S., the U.K. and China, with additional locations in India and a full-service distributor based in Japan.